PL366158A1 - Novel fibroblast growth factors - Google Patents

Novel fibroblast growth factors

Info

Publication number
PL366158A1
PL366158A1 PL01366158A PL36615801A PL366158A1 PL 366158 A1 PL366158 A1 PL 366158A1 PL 01366158 A PL01366158 A PL 01366158A PL 36615801 A PL36615801 A PL 36615801A PL 366158 A1 PL366158 A1 PL 366158A1
Authority
PL
Poland
Prior art keywords
growth factors
fibroblast growth
novel fibroblast
novel
factors
Prior art date
Application number
PL01366158A
Other languages
English (en)
Polish (pl)
Inventor
Peter W. Bringmann
Daryl Faulds
Bronislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL366158A1 publication Critical patent/PL366158A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01366158A 2000-12-08 2001-12-10 Novel fibroblast growth factors PL366158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
PL366158A1 true PL366158A1 (en) 2005-01-24

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366158A PL366158A1 (en) 2000-12-08 2001-12-10 Novel fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (enExample)
EP (1) EP1389237A2 (enExample)
JP (1) JP2005506275A (enExample)
KR (1) KR20040052442A (enExample)
CN (1) CN1518597A (enExample)
AU (1) AU2603402A (enExample)
BG (1) BG107888A (enExample)
BR (1) BR0116507A (enExample)
CA (1) CA2431374A1 (enExample)
CZ (1) CZ20031570A3 (enExample)
EE (1) EE200300269A (enExample)
HU (1) HUP0400657A1 (enExample)
IL (1) IL156259A0 (enExample)
MX (1) MXPA03005142A (enExample)
NO (1) NO20032573L (enExample)
PL (1) PL366158A1 (enExample)
RU (1) RU2329058C2 (enExample)
SI (1) SI21372A (enExample)
SK (1) SK7012003A3 (enExample)
WO (1) WO2002046424A2 (enExample)
ZA (1) ZA200305236B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
WO2004090112A2 (en) 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
PT1232264E (pt) * 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
AU2603402A (en) 2002-06-18
WO2002046424A2 (en) 2002-06-13
EP1389237A2 (en) 2004-02-18
SI21372A (sl) 2004-06-30
AU2002226034A2 (en) 2002-06-18
CZ20031570A3 (cs) 2004-01-14
ZA200305236B (en) 2005-06-29
HUP0400657A1 (en) 2006-04-28
CA2431374A1 (en) 2002-06-13
MXPA03005142A (es) 2004-10-15
RU2003119657A (ru) 2005-02-27
KR20040052442A (ko) 2004-06-23
EE200300269A (et) 2003-10-15
US20080057076A1 (en) 2008-03-06
NO20032573L (no) 2003-07-22
NO20032573D0 (no) 2003-06-06
IL156259A0 (en) 2004-01-04
US20020151496A1 (en) 2002-10-17
BR0116507A (pt) 2004-01-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
WO2002046424A3 (en) 2003-11-27
BG107888A (bg) 2004-08-31
SK7012003A3 (en) 2004-04-06

Similar Documents

Publication Publication Date Title
IL156259A0 (en) Novel fibroblast growth factors
IL150544A0 (en) Novel biarylcarboxamides
CA98770S (en) Pantiliner
AU8860401A (en) Novel guanidinobenzamides
AU3924300A (en) Fibroblast growth factor-20
AU1217102A (en) Novel arylalkane-sulfonamides
IL153471A0 (en) Novel arylethene-sulfonamides
AU4851200A (en) Fibroblast growth factor 11
GB2414798B (en) Fibroblast growth factor binding assay
GB0106208D0 (en) Tableware
GB0022992D0 (en) Novel vompounds
CA90931S (en) Pantiliner
GB0013272D0 (en) Neurotropic growth factor
AU9149301A (en) Growth factor complex
GB0000829D0 (en) Growth inhibitor
GB0019524D0 (en) Novel use
TW418600U (en) Convex flowerpot
CA90930S (en) Pantiliner
PL110774U1 (en) Flowerpot
TW425839U (en) Flowerpot
GB0005769D0 (en) Pot
EG22115A (en) Greenhouse
CA86570S (en) Greenhouse
SI1259508T1 (en) Novel biarylcarboxamides
GB0031651D0 (en) Culturing tissue

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)